The first phase 3 trials are due to start in the first half of next year, using devices manufactured at GSK’s facility in Evreux, France. “If successful, this could lead to regulatory ...

GSK reveals steep fall in vaccine sales, backs outlook 07:13 , Graeme Evans GSK today reported a ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

Kering, GSK and Holcim are adopting science-based targets aimed at protecting land and water globally.

European stocks closed broadly higher on Tuesday with investors largely making cautious moves, digesting mixed earnings updates and ...

GSK’s NgG shot is based on generalised modules ... approximately 750 healthy adult subjects in the US, the UK, France, Germany, Spain, Brazil, the Philippines, and South Africa, with a readout ...